Cargando…
BRAF mutations, microsatellite instability status and cyclin D1 expression predict metastatic colorectal patients’ outcome
BACKGROUND: The significance of BRAF mutations, microsatelite instability (MSI) status and cyclin D1 expression in patients with metastatic colorectal cancer (mCRC) was evaluated. METHODS: Primary tumours from 144 patients treated for mCRC were assessed for BRAF (V600E) mutation, MSI status and cycl...
Autores principales: | Saridaki, Z, Papadatos-Pastos, D, Tzardi, M, Mavroudis, D, Bairaktari, E, Arvanity, H, Stathopoulos, E, Georgoulias, V, Souglakos, J |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2883698/ https://www.ncbi.nlm.nih.gov/pubmed/20485284 http://dx.doi.org/10.1038/sj.bjc.6605694 |
Ejemplares similares
-
A Case Presentation of a Patient with Microsatellite Instability and BRAF Mutant Metastatic Colon Cancer and Bibliography Update
por: Thomopoulou, K., et al.
Publicado: (2019) -
Correlation of BRCA1, TXR1 and TSP1 mRNA expression with treatment outcome to docetaxel-based first-line chemotherapy in patients with advanced/metastatic non-small-cell lung cancer
por: Papadaki, C, et al.
Publicado: (2011) -
Comparison of EGFR and K-RAS gene status between primary tumours and corresponding metastases in NSCLC
por: Kalikaki, A, et al.
Publicado: (2008) -
Prognostic and predictive value of common mutations for treatment response and survival in patients with metastatic colorectal cancer
por: Souglakos, J, et al.
Publicado: (2009) -
‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer
por: Pallis, A G, et al.
Publicado: (2007)